Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

@article{Andresen2008EffectsO5,
  title={Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.},
  author={Viola Andresen and Victor M. Montori and Jutta Keller and Colin P West and Peter Layer and Michael Camilleri},
  journal={Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association},
  year={2008},
  volume={6 5},
  pages={
          545-55
        }
}
BACKGROUND & AIMS We performed a systematic review and meta-analyses to estimate treatment efficacy and constipation rate of 5-hydroxytryptamine (serotonin) (5-HT(3)) antagonists in patients with nonconstipated (NC) or diarrhea-predominant (D)-irritable bowel syndrome (IBS). METHODS Two reviewers independently searched MEDLINE, EMBASE, and Web of Science (January 1, 1966 to December 15, 2006) for randomized controlled trials of 5-HT(3) antagonists in IBS reporting clinical end points of the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 70 CITATIONS, ESTIMATED 44% COVERAGE

Subtypes of irritable bowel syndrome in children: prevalence at diagnosis and at follow-up.

  • The Journal of pediatrics
  • 2014
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.

  • British journal of pharmacology
  • 2009
VIEW 18 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Brain-gut axis: from basic understanding to treatment of IBS and related disorders.

  • Journal of pediatric gastroenterology and nutrition
  • 2012
VIEW 13 EXCERPTS
CITES BACKGROUND

Review article: the pharmacological causes of colon ischaemia.

  • Alimentary pharmacology & therapeutics
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Management Options for Irritable Bowel Syndrome.

  • Mayo Clinic proceedings
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2007

Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.

  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2007

Safety and efficacy of 0 . 5 mg qd , 1 mg qd , and 1 mg bid alosetron hydrochloride in women with chronic , severe diarrheapredominant IBS ( IBSD )

R Krause, V Ameen, S Gordon
  • 2006

Relief of symptoms in irritable bowel syndrome with diarrhea predominance ( IBSD ) patients decreases after blinded withdrawal of cilansetron treatment

CF Francisconi, D Drossman, EA Mayer
  • Gastroenterology
  • 2005

Cilansetron in irritable bowel syndrome with diarrhea predominance ( IBSD ) : efficacy and safety in a 3 - month US study

P Miner, DB Stanton, F Carter
  • Am J Gastroenterol
  • 2004